ART Advanced Research Technologies Inc.
2300 Alfred-Nobel Blvd.
Saint-Laurent, QC H4S 2A4
ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare. TSX ticker symbol: ARA.
World Wide Web: www.art.ca
Phone: (514) 832-0777
FAX: (514) 832-0778
E-mail: info@art.ca
Sébastien Gignac, Chairman of the Board, President and CEO
Ext. 237
E-mail: sgignac@art.ca
Jacques Bédard, Chief Financial Officer
Ext. 233
E-mail: jbedard@art.ca
Dino Dicamillo, Vice-President, Global Sales and Marketing, Preclinical
Ext. 279
E-mail: ddicamillo@art.ca
Marie-France Nantel, Corporate Secretary
Ext. 252
E-mail: mfnatel@art.ca
Joe Kozikowski, Chief Medical Officer
Ext. 273
E-mail: jk@art.ca
Ani Armenian, Corporate Communications Manager
Ext. 245
E-mail: aarmenia@art.ca
Mario Khayat, Vice-President, Optical Products
Ext. 239
E-mail: mkhayat@art.ca
Saint-Laurent, QC H4S 2A4
ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare. TSX ticker symbol: ARA.
World Wide Web: www.art.ca
Phone: (514) 832-0777
FAX: (514) 832-0778
E-mail: info@art.ca
Sébastien Gignac, Chairman of the Board, President and CEO
Ext. 237
E-mail: sgignac@art.ca
Jacques Bédard, Chief Financial Officer
Ext. 233
E-mail: jbedard@art.ca
Dino Dicamillo, Vice-President, Global Sales and Marketing, Preclinical
Ext. 279
E-mail: ddicamillo@art.ca
Marie-France Nantel, Corporate Secretary
Ext. 252
E-mail: mfnatel@art.ca
Joe Kozikowski, Chief Medical Officer
Ext. 273
E-mail: jk@art.ca
Ani Armenian, Corporate Communications Manager
Ext. 245
E-mail: aarmenia@art.ca
Mario Khayat, Vice-President, Optical Products
Ext. 239
E-mail: mkhayat@art.ca
Areas of Expertise:
| Information and Media Resources from Sources | |||||||||
| Sources Directory | The directory of experts, contacts and
media spokespersons. Find how to include yourself in Sources. |
||||||||
| Sources Calendar | Check out newsworthy events from across Canada. | ||||||||
| News Releases | Media releases from clients of the Sources media relations service. | ||||||||
| Media Names & Numbers | Directory of Canada's print and broadcast media. | ||||||||
| Parliamentary Names & Numbers | Full contact information for government, political parties, lobbyists, and embassies. | ||||||||
© Sources 2008. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed.